Health Care [ 9/12 ] | Pharmaceuticals [ 39/75 ]
NASDAQ | Common Stock
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms.
Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 26 | -0.55 Increased by +0.65% | -0.52 Decreased by -5.04% |
| Nov 13, 25 | -0.34 Increased by +46.88% | -0.45 Increased by +24.44% |
| Aug 14, 25 | -0.43 Increased by +55.67% | -0.46 Increased by +6.52% |
| May 13, 25 | -0.54 Increased by +14.16% | -0.58 Increased by +6.76% |
| Mar 31, 25 | -0.55 Decreased by -266.67% | -0.71 Increased by +22.54% |
| Nov 7, 24 | -0.64 Decreased by -6.67% | -0.70 Increased by +8.57% |
| Aug 7, 24 | -0.97 Decreased by -64.41% | -1.14 Increased by +14.91% |
| May 15, 24 | -0.63 Decreased by -16.67% | -0.58 Decreased by -8.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | 86.45 M Increased by +375.69% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -30.92 M Increased by +4.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -25.42 M Increased by +54.63% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 412.00 K Decreased by -69.84% | -33.46 M Increased by +10.02% | Decreased by -8.12 K% Decreased by -198.35% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -31.36 M Increased by +16.93% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -32.23 M Increased by +13.57% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -56.04 M Decreased by -66.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 1.37 M Increased by +N/A% | -37.18 M Decreased by -128.88% | Decreased by -2.72 K% Decreased by N/A% |